Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes.

Abstract

This study evaluated whether adding sodium-glucose cotransporter-2 inhibitors (SGLT2i) and/or glucagon-like peptide-1 receptor agonists (GLP1-RA) to insulin reduced weight and glycemia in people with type 1 diabetes. This retrospective analysis of electronic health records evaluated 296 people with type 1 diabetes over 12 months after medications were first prescribed. Four groups were defined: control n= 80, SGLT2i n= 94, GLP1-RA n= 82, and combination of drugs (Combo) n= 40. We measuredchanges at 1year in weight and glycated hemoglobin (HbA1c). The control group did not have changes in weight or glycemic control. The mean (SD) percentage weight loss after 12 months was 4.4%(6.0%), 8.2% (8.5%), and 9.0%(8.4%) in the SGLT2i, GLP1-RA, and Combo groups, respectively (p< 0.001). The Combo group lost the most weight (p <0.001). The HbA1c reduction was 0.4% (0.7%), 0.3% (0.7%), and 0.6% (0.8%) in the SGLT2i, GLP1-RA, and Combo groups, respectively (p< 0.001). The Combo group had the biggest improvements in glycemic control and total and low-density lipoprotein cholesterol compared with baseline (all p <0.01). Severe adverse events were similar between all the groups, with no increased risk of diabetic ketoacidosis. The SGLT2i and GLP1-RA agents on their own improved body weight and glycemia, but combining the medications resulted in more weight loss. Treatment intensification appears to result in benefits with no difference in severe adverse events.